In the last year, an estimated 36.7 million people were living with the Human Immunodeficiency Virus (HIV), with 5,700 new infections occurring daily. Currently, there are 26 FDA approved antiretroviral drugs for the treatment of HIV; however, drug resistance still remains a major problem associated with the current treatments. GS-8374 is a novel protease inhibitor that makes use of a diethyl phosphonate group at the P1 position and has a superior resistance profile when compared to that of current FDA approved inhibitors. For this project three new analogues of GS-8374 were synthesized and tested against the I84V mutant, which confers resistance to most protease inhibitors, of HIV protease.

• This report represents the work of one or more WPI undergraduate students submitted to the faculty as evidence of completion of a degree requirement. WPI routinely publishes these reports on its website without editorial or peer review.

Creator

• Falci, Jessica Rose

Contributors

• Ali, Akbar

Publisher

• Worcester Polytechnic Institute

Identifier

• E-project-042617-233747

Advisor

• Dittami, James P.

Year

• 2017

Sponsor

• University of Massachusetts Medical Center, Worcester Massachusetts

Date created

• 2017-04-26

Resource type

• Major Qualifying Project

Major

• Chemistry

Rights statement

• In Copyright